Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry.
Investment Stage: Series E
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 31.05.2023 | Carmot The... | carmot.us | $150M | United Sta... |
Mentions in press and media 6
| Date | Title | Description |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 30.10.2024 | GlycoMimetics To Acquire Crescent Biopharma | GlycoMimetics (NASDAQ: GLYC), a Rockville, MD-based late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, acquired Crescent Biopharma, Inc., a biotechnology company advancing a pipeli... |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M. The round added Frazier Life Sc... |
| 21.03.2024 | Cybin Raises $150M to Advance Psychedelic Therapy for Depression | What You Should Know: – Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included partici... |